<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0311222867
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ARTHOSAVE 200 mg tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HYDROXYCHLOROQUINE SULFATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        127
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        P01BA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ARTHOSAVE belongs to the family of medicines called Antimalarial. This medicine is used to prevent and to treat mosquito-generated malaria infection which is contracted in tropical countries<em>.</em><em> </em>It is also used in the treatment of arthritis to help relieve inflammation, swelling, stiffness, and joint pain and to help control the symptoms of lupus erythematosus (lupus; SLE). This medicine may be given alone or with one or more other medicines. ARTHOSAVE is available only with your doctor&#39;s prescription.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make.</p><p>&nbsp;</p><p><strong><u>Do not use ARTHOSAVE</u></strong></p><p>Tell your doctor if you have ever had any unusual or allergic reaction to hydroxychloroquine or chloroquine. Also tell your health care professional if you are allergic to any other substances, such as foods, preservatives, or dyes.</p><p>Unless you are taking it for malaria, use of this medicine is not recommended during pregnancy.</p><p>Children are especially sensitive to the effects of ARTHOSAVE. This may increase the chance of side effects during treatment. Overdose is especially dangerous in children. Taking as few as 3 or 4 tablets (250 -milligrams [mg] strength) of chloroquine has resulted in death in small children. Because ARTHOSAVE is so similar to chloroquine, it is probably just as toxic.</p><p>Many medicines have not been studied specifically in older people. Therefore, it may not be known whether they work exactly the same way they do in younger adults or if they cause different side effects or problems in older people. There is no specific information comparing use of ARTHOSAVE in the elderly with use in other age groups.</p><p>&nbsp;</p><p><strong><u>Take special care with ARTHOSAVE</u></strong></p><p>The presence of other medical problems may affect the use of ARTHOSAVE. Make sure you tell your doctor if you have any other medical problems, especially:</p><ul><li>Blood disease (severe) - ARTHOSAVE may cause blood disorders;</li><li>Eye or vision problems - ARTHOSAVE may cause serious eye side effects, especially in high doses;</li><li>Glucose-6-phosphate dehydrogenase (G6PD) deficiency - ARTHOSAVE may cause serious blood side effects in patients with this deficiency;</li><li>Kidney disease - There may be an increased chance of side effects in patients with kidney disease;</li><li>Liver disease - May decrease the removal of ARTHOSAVE from the blood, increasing the chance of side effects;</li><li>Nerve or brain disease (severe), including convulsions (seizures) - ARTHOSAVE may cause muscle weakness and, in high doses, seizures;</li><li>Porphyria - ARTHOSAVE may worsen the symptoms of porphyria;</li><li>Psoriasis - ARTHOSAVE may bring on severe attacks of psoriasis;</li><li>Stomach or intestinal disease (severe) - ARTHOSAVE may cause dyspepsia or stomach upset.</li></ul><p>&nbsp;</p><p>If you are living in, or will be traveling to, an area where there is a chance of getting malaria, the following mosquito-control measures will help to prevent infection:</p><ul><li>If possible, sleep under mosquito netting to avoid being bitten by malaria-carrying mosquitoes.</li><li>Wear long-sleeved shirts or blouses and long trousers to protect your arms and legs, especially from dusk through dawn when mosquitoes are out.</li><li>Apply mosquito repellent to uncovered areas of the skin from dusk through dawn when mosquitoes are out.</li></ul><p>&nbsp;</p><p><strong><u>Taking ARTHOSAVE with other medicines, herbal or dietary supplements</u></strong></p><p>Although certain medicines should not be used together at all, in other cases 2 different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your health care professional if you are taking any other prescription or non-prescription (over-the- counter [OTC]) medicine.</p><p>&nbsp;</p><p>As hydroxychloroquine may enhance the effects of a hypoglycaemic treatment, a decrease in doses of insulin or antidiabetic drugs may be required.</p><p>&nbsp;</p><p><strong><u>Taking ARTHOSAVE with food and drink</u></strong></p><p>It is better to take it with meals or milk to prevent stomach upset, unless otherwise directed by your doctor.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Pregnancy and breast-feeding</u></strong></p><p>Unless you are taking it for malaria, use of this medicine is not recommended during pregnancy. In animal studies, ARTHOSAVE has been shown to cause damage to the central nervous system (brain and spinal cord) of the fetus, including damage to hearing and sense of balance, bleeding inside the eyes, and other eye problems. However, when given in low doses (once a week) to prevent malaria, this medicine has not been shown to cause birth defects or other problems in pregnant women.</p><p>&nbsp;</p><p>A very small amount of ARTHOSAVE passes into the breast milk. It has not been reported to cause problems in nursing babies to date. However, babies and children are especially sensitive to the effects of ARTHOSAVE.</p><p>&nbsp;</p><p><strong><u>Driving and using machines</u></strong></p><p>Hydroxychloroquine may cause blurred vision, difficulty in reading, or other change in vision. It may also cause some people to become dizzy or lightheaded. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are dizzy or are not alert or able to see well. If these reactions are especially bothersome, check with your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>It is very important that you take this medicine only as directed. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. To do so may increase the chance of serious side effects. If you are taking this medicine to help keep you from getting malaria, keep taking it for the full time of treatment. If you already have malaria, you should still keep taking this medicine for the full time of treatment even if you begin to feel better after a few days. This will help to clear up your infection completely. If you stop taking this medicine too soon, your symptoms may return. Do not give this medication to anyone else and use it as an antimalarial only for the trip for which it has been prescribed. ARTHOSAVE works best when you take it on a regular schedule. For example, if you are to take it once a week to prevent malaria, it is best to take it on the same day each week. Or if you are to take 2 doses a day, 1 dose may be taken with breakfast and the other with the evening meal. Make sure that you do not miss any doses. If you have any questions about this, check with your health care professional.</p><p>&nbsp;</p><p>If your symptoms do not improve within a few days (or a few weeks or months for arthritis), or if they become worse, check with your doctor.</p><p>&nbsp;</p><p>The dose of ARTHOSAVE will be different for different patients. Follow your doctor&#39;s orders or the directions on the label. The following information includes only the average doses of ARTHOSAVE sulfate. If your dose is different, do not change it unless your doctor tells you to do so. The number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are taking ARTHOSAVE.</p><p>&nbsp;</p><p><strong>For prevention of malaria:</strong></p><ul><li>Adults -- 400 mg of ARTHOSAVE sulfate once every seven days.</li><li>Children -- Dose is based on body weight and must be determined by your doctor. The usual dose is</li><li>6.5 mg per kilogram (kg) (2.9 mg per pound) of body weight once every seven days.</li></ul><p>&nbsp;</p><p><strong>For treatment of malaria:</strong></p><ul><li>Adults -- 800 mg as a single dose. This may sometimes be followed by a dose of 400 mg six to eight hours after the first dose, then 400 mg once a day on the second and third days.</li><li>Children -- Dose is based on body weight and must be determined by your doctor. The usual dose is</li><li>32.3 mg per kg (14.6 mg per pound) of body weight taken over a period of three days.</li></ul><p>&nbsp;</p><p><strong>For treatment of lupus erythematous:</strong></p><ul><li>Adults -- The average initial dose is 400 mg once or twice daily.</li></ul><p>&nbsp;</p><p><strong>For treatment of rheumatoid arthritis:</strong></p><ul><li>Adults -- The usual initial dose is 400 - 600 mg per day.</li></ul><p>&nbsp;</p><p><strong>For patients taking ARTHOSAVE to prevent malaria:</strong></p><ul><li>Your doctor may want you to start taking this medicine 1 to 2 weeks before you travel to an area where there is a chance of getting malaria. This will help you to see how you react to the medicine. Also, it will allow time for your doctor to change to another medicine if you have a reaction to this medicine.</li><li>Also, you should keep taking this medicine while you are in the area with malaria and for an additional 8 weeks after you leave the area because the malaria parasite has a complex life cycle and may persist for some time in your body. No medicine will protect you completely from malaria. However, to protect you as completely as possible, it is important to keep taking this medicine for the full time your doctor ordered. Also, if fever develops during your travels or within 2 months after you leave the area, check with your doctor immediately.</li></ul><p>&nbsp;</p><p><strong>For patients taking ARTHOSAVE for arthritis or lupus:</strong></p><ul><li>This medicine must be taken regularly as ordered by your doctor in order for it to help you. It may take several months before you feel the full benefit of this medicine.</li></ul><p>&nbsp;</p><p><strong><u>If you take more ARTHOSAVE than you should</u></strong></p><p>The 4-aminoquinoline compounds are very rapidly and completely absorbed after ingestion, and in accidental overdosage, or rarely with lower dosages in hypersensitive patients, toxic symptoms may occur within 30 minutes. These consist of headache, drowsiness, visual disturbances, cardiovascular collapse, and convulsions, followed by sudden and early respiratory and cardiac arrest.</p><p>&nbsp;</p><p><strong>Treatment </strong>is symptomatic and must be prompt with immediate evacuation of the stomach by emesis (at home, before transportation to the hospital) or gastric lavage until the stomach is completely emptied.</p><p>&nbsp;</p><p>Contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately.</p><p>&nbsp;</p><p><strong><u>Missed dose</u></strong></p><p>If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention. When this medicine is used for short periods of time, side effects usually are rare. However, when it is used for a long time and/or in high doses, side effects are more likely to occur and may be serious.</p><p>&nbsp;</p><p><em>Check</em><em> with your doctor immediately </em>if any of the following side effects occur:</p><p>&nbsp;</p><p><strong><em>Less common: </em></strong>Blurred vision or any other change in vision - this side effect may also occur or get worse after you stop taking this medicine;</p><p>&nbsp;</p><p><strong><em>Rare: </em></strong>Convulsions (seizures); increased muscle weakness; mood or other mental changes; ringing or buzzing ears or any loss of hearing; sore throat and fever, unusual bleeding or bruising; unusual tiredness, weakness; <em>Symptoms of overdose: </em>Drowsiness; headache; increased excitability.</p><p>&nbsp;</p><p>Other side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine.</p><p>&nbsp;</p><p>However, check with your doctor if any of the following side effects continue or are bothersome:</p><p>&nbsp;</p><p><strong><em>More common: </em></strong>Diarrhea; difficulty in seeing to read; headache; itching (more common in black patients); loss of appetite, nausea or vomiting; stomach cramps or pain;</p><p>&nbsp;</p><p><strong><em>Less common: </em></strong>Bleaching of hair or increased hair loss; blue-black discoloration of skin, fingernails, or inside of mouth; dizziness or lightheadedness; nervousness or restlessness; skin rash.</p><p>&nbsp;</p><p>Other side effects not listed above may also occur in some patients. If you notice any other effects, check with doctor.</p><p>&nbsp;</p><p>Check with your doctor immediately if blurred vision, difficulty in reading, or any other change in vision occurs during or after long-term treatment. Your doctor may want you to have your eyes checked by an ophthalmologist (eye doctor).</p><p>&nbsp;</p><p>ARTHOSAVE may cause abnormal color vision, blurred vision, difficulty in reading, or other change in vision. It may also cause some people to become dizzy or lightheaded. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are dizzy or are not alert or able to see well. If these reactions are especially bothersome, check with your doctor. Malaria is spread by mosquitoes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep out of the reach of children. Overdose of ARTHOSAVE is very dangerous in children.</li><li>Store below 25&deg;C.</li><li>Do not store in the bathroom, near the kitchen sink, or in other damp places.</li><li>Do not keep outdated medicine or medicine no longer needed. Be sure that any discarded medicine is out of the reach of children.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is Hydroxychloroquine Sulfate USP.</li><li>The other ingredients are Croscarmellose Sodium, Magnesium stearate, Colloidal silicon dioxide, microcrystalline cellulose, Hydroxypropyl cellulose, Hydroxymethylcellulose 2910 USP E5, Polyethylene glycol 8000, Titanium dioxide USP and purified water.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                White, Capsule-Shaped, Biconvex, film-coated tablet with flat edges. One side engraved APO, HCQ 200 on other side.

It is available in 100 Tablet bottle.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised in 03/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي الدواء ارثوسيف إلى فئة من الأدوية تسُمى مضادات الملاريا. ويسُتخدم هذا الدواء للوقاية والعلاج من عدوى ملاريا البعوض المنتشرة في البلدان الاستوائية. يسُتخدم هذا الدواء أيضًا لعلاج التهاب المفاصل للمساعدة في تخفيف الالتهاب والتورم والتيبس وألم المفاصل وكذلك للمساعدة في السيطرة على أعراض الذأبة الحمامية الشاملة. ويمكن إعطاء هذا الدواء بمفرده أو مع واحد أو أكثر من الأدوية الأخرى. ويجب عدم استخدام الدواء ارثوسيف إلا بموجب وصفة طبية من الطبيب.<br />-</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>عند تقرير استخدام أي دواء، يجب الموازنة بين المخاطر والفوائد المتوقعة من استخدام ذلك الدواء. وهذا القرار يأخذه الطبيب على أساس فحص حالتك.</p><p><br /><u><strong>أ- متى يجب عدم استخدام ارثوسيف:</strong></u></p><ul><li>ينبغي إخبار الطبيب بأي رد فعل غير عادي أو تحسسي تجاه الدواء ارثوسيف أو مادة كلوروكين. ويجب أيضًا على المريض إخبار الطبيب إذا كان يعاني من حساسية تجاه أي مواد أخرى مثل الأطعمة أو المواد الحافظة أو الصبغات.</li><li>لا يوصى باستخدام هذا الدواء أثناء الحمل ما لم يكن استخدامه لعلاج الملاريا.</li><li>الأطفال أكثر حساسية لتأثيرات الدواء ارثوسيف. ومن ثم قد يزيد احتمال حدوث أثار جانبية أثناء العلاج. ولذا تكون الجرعة الزائدة عن الحاجة خطيرة بشكل خاص في الأطفال. وقد أدى تناول جرعة صغيرة لا تتجاوز 3 أو 4 أقراص (تركيز 250 ملجم) من مادة كلوروكين إلى وفاة أطفال صغار. وحيث إن التشابه كبير بين مادة ارثوسيف ومادة كلوروكين، فإنه يرُجح أن تكون على الدرجة نفسها من السمية.</li><li>هناك كثير من الأدوية التي لم تدُرس بصورة دقيقة في فئة كبار السن. لذا، قد لا تكون هناك معلومات عما إذا كان مفعول تلك الأدوية في كبار السن هو نفسه في البالغين الأصغر سنا أم أنها تسبب آثارًا جانبية أو مشكلات مختلفة في كبار السن. كما أنه لا توجد معلومات محددة عن الاستخدام المقارن لدواء ارثوسيف في كبار السن واستخدامه في الفئات العمرية الأخرى.</li></ul><p>&nbsp;</p><p><u><strong>ب- الاحتياطات عند استخدام ارثوسيف:</strong></u></p><p>قد يؤثر وجود مشكلات طبية أخرى في استخدام الدواء ارثوسيف. احرص على إخبار الطبيب بأي مشكلات طبية أخرى تعاني منها، خصوصًا ما يلي:</p><ul><li>أمراض في الدم )خطيرة( - قد يسبب ارثوسيف اضطرابات في الدم</li><li>مشكلات في العين أو الإبصار - قد يسبب ارثوسيف آثارًا جانبية خطيرة على العين، خصوصًا مع استخدام جرعات عالية،</li><li>نقص نازعة هيدروجين جلوكوز- 6-فوسفات - يمكن أن يسبب ارثوسيف آثارًا جانبية خطيرة في الدم لدى المرضى المصابين بنقص هذه المادة،</li><li>أمراض الكلى - هناك احتمال لحدوث آثار جانبية لدى المصابين بأمراض كلوية،</li><li>أمراض الكبد - قد تؤدي إلى نقص التخلص من مادة ارثوسيف من الدم ومن ثم زيادة احتمال حدوث آثار جانبية،</li><li>أمراض الأعصاب أو المخ )خطيرة( بما في ذلك الاختلاجات )نوبات الصرع( - قد يسبب ارثوسيف ضعف العضلات و - في حالة الجرعات العالية - نوبات صرع،</li><li>البرفرية - قد يؤدي ارثوسيف إلى تفاقم أعراض حالة البرفرية،</li><li>الصدفية - قد يسُبب ارثوسيف حدوث حالات صدفية خطيرة،</li><li>أمراض المعدة أو الأمعاء )خطيرة( - قد يسبب ارثوسيف عسر هضم أو اضطراب المعدة.</li></ul><p>&nbsp;</p><p>إذا كنت تعيش في - أو ستسافر إلى - منطقة يحُتمل تعرضك فيها للإصابة بالملاريا؛ فستساعدك تدابير مكافحة البعوض التالية على الوقاية من العدوى:</p><ul><li>النوم تحت ناموسية - إن أمكن - لتجنب عض البعوض الحامل لعدوى الملاريا.</li><li>ارتداء قمصان أو بلوزات طويلة الأكمام وبنطلونات طويلة السيقان لحماية الأيدي والأرجل خصوصًا خلال فترة انتشار البعوض من وقت الغسق حتى الفجر.</li><li>استعمال دهان طارد للبعوض لتغطية المناطق المكشوفة من الجلد والبشرة خلال فترة انتشار البعوض من وقت الغسق حتى الفجر.</li></ul><p>&nbsp;</p><p><u><strong>ج- التداخلات الدوائية من أخذ هذا المستحضر مع أي ادوية اخرى او اعشاب او مكملات غذائية:</strong></u><br />على الرغم من أن بعض الأدوية لا ينبغي أن تستخدم جنبا إلى جنب في كل شيء، في حالات أخرى اثنين من الأدوية المختلفة يمكن استخدامها جنبا إلى جنب حتى لو قد يحدث التفاعل. في هذه الحالات، قد يريد طبيبك تغيير الجرعة، أو قد تكون هناك احتياطات أخرى لازمة. أخبر أخصائي الرعاية الصحية إذا كنت تأخذ أي وصفة طبية أو غيرها من غير وصفة طبية&nbsp;(OTC).<br />كما قد يؤدي هيدروكسي كلوروكوين إلى تعزيز آثار علاج سكر الدم )إنخفاض(، قد تكون هناك حاجة إلى انخفاض جرعات من الأنسولين أو الأدوية المضادة لمرض السكر.</p><p>&nbsp;</p><p><u><strong>د- تناول ارثوسيف مع الطعام والشراب:</strong></u><br />يؤخذ هذا الدواء مع الوجبات أو اللبن لتقليل الاضطراب المحتمل للمعدة، ما لم يصف الطبيب خلاف ذلك.</p><p>&nbsp;</p><p><u><strong>ه- الحمل والرضاعة الطبيعية:</strong></u><br />لا يوصى باستخدام هذا الدواء أثناء الحمل ما لم يكن استخدامه لعلاج الملاريا. في الدراسات التي أجُريت على الحيوانات؛ تبين أن الدواء ارثوسيف يسبب تلفا للجهاز العصبي المركزي (المخ والحبل الشوكي) للأجنة بما في ذلك تلفا للسمع وحاسة التوازن ونزيف داخل العينين وغير ذلك من اضطرابات العينين. على الرغم من ذلك، لم يتبين أن هذا الدواء يسبب عيوب خلقية أو مشكلات أخرى في النساء الحوامل عند إعطاء جرعات منخفضة منه (مرة واحدة في الأسبوع) للوقاية من الملاريا.</p><p>تفُرز مادة ارثوسيف في لبن الثدي بكميات قليلة. ولم ترد أي معلومات حتى الآن بأنها تسبب مشكلات في الأطفال الرضع. ورغم ذلك؛ يكون الأطفال الرضع وغير الرضع أكثر حساسية لتأثيرات الدواء ارثوسيف.</p><p><br /><u><strong>و- تأثيره على القيادة واستخدام الآلات:</strong></u><br />هيدروكسي كلوروكوين قد يسبب عدم وضوح الرؤية، وصعوبة في القراءة، أو تغيير آخر في الرؤية. فإنه قد يسبب أيضا بعض الناس بالدوار أو بدوخة. تأكد من أنك تعرف كيف تتفاعل مع هذا الدواء قبل أن تقود، استخدام الآلات، أو القيام بأي شيء آخر يمكن أن يكون خطرا إذا كنت مصابا بالدوار أو ليست في حالة تأهب أو قادرا على رؤية جيدة. إذا كانت ردود الفعل هذه مزعجة، تحقق مع طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>من المهم جدًا استخدام هذا الدواء حسب تعليمات الطبيب بالضبط. لا تتناول جرعة كبيرة من هذا الدواء، ولا تتناول هذا الدواء بشكل متكرر، ولا تتناوله لفترات أطول من التي حددها لك الطبيب. إذا خالفت هذه التعليمات فقد يزيد احتمال تعرضك لآثار جانبية خطيرة. وإذا كنت تستخدم هذا العلاج للوقاية من الملاريا؛ فحافظ على استخدامه بانتظام طوال مدة العلاج. إذا كنت مصابا بالملاريا فعلا؛ً فينبغي الاستمرار في استخدام هذا الدواء طوال مدة العلاج حتى لو بدأت تشعر بتحسن بعد بضعة أيام. سيساعد هذا على القضاء على العدوى تمامًا. إذا توقفت عن تناول هذا الدواء في وقت مبكر جدًا، فقد تعود إليك الأعراض ثانيةً. لا تعُط هذا الدواء إلى أي شخص آخر، واستعمله كعلاج مضاد للملاريا خلال الرحلة التي وُصف لك من أجلها فقط. يتحقق أفضل مفعول للدواء ارثوسيف عند&nbsp; استخدامه وفقا لجدول منتظم. على سبيل المثال، إذا كنت ستأخذه مرة واحدة في الأسبوع للوقاية من الملاريا؛ فمن الأفضل تناوله في وقت واحد محدد كل أسبوع. وإذا كنت ستأخذ جرعتين في اليوم، فيمكن تناول جرعة واحدة مع وجبة الإفطار والجرعة الثانية مع وجبة العشاء. احرص على عدم فقدان أي جرعة. إذا كان لديك أي أسئلة عن هذا الموضوع؛ فاستشر الطبيب الخاص بك.</p><p>&nbsp;</p><p>إذا لم تتحسن الأعراض التي تعاني منها خلال بضعة أيام (أو بضعة أسابيع أو أشهر في حالة التهاب المفاصل) أو إذا تفاقمت الأعراض؛ فاستشر الطبيب.</p><p><br />تختلف جرعة ارثوسيف من مريض لآخر. ويجب اتباع تعليمات الطبيب أو التعليمات الموجودة على الملصق. توضح المعلومات التالية الجرعات المتوسطة فقط من مادة هيدروكسيكوين سلفات. إذا كانت الجرعة الخاصة بك مختلفة عن الواردة هنا، فلا تغيرها ما لم يطلب الطبيب منك فعل ذلك يتوقف عدد الجرعات التي تأخذها كل يوم والوقت الفاصل بين الجرعات وطول المدة العلاجية على المشكلة الطبية التي تأخذ من أجلها الدواء ارثوسيف.</p><p>&nbsp;</p><p><strong>للوقاية من الملاريا:</strong></p><ul><li>للبالغين: 400 ملجم من ارثوسيف سلفات مرة واحدة كل 7 أيام.</li><li>للأطفال: تتوقف الجرعة على وزن الجسم ويجب تحديدها بواسطة الطبيب. الجرعة العادية هي 5.6 ملجم لكل كيلو جرام (9.2 ملجم لكل رطل)&nbsp;من وزن الجسم كل 7 أيام.</li></ul><p>&nbsp;</p><p><strong>لعلاج الملاريا:</strong></p><ul><li>للبالغين: 800 ملجم كجرعة واحدة. أحيانا تتُبع هذه الجرعة بجرعة أخرى 400 ملجم بعدها بمدة 6 إلى 8 ساعات، ثم تؤخذ جرعة 400 ملجم مرة واحدة في اليوم في اليومين الثاني والثالث.</li><li>للأطفال: تتوقف الجرعة على وزن الجسم ويجب تحديدها بواسطة الطبيب. الجرعة العادية هي 3.32 ملجم لكل كيلو جرام (6.14 ملجم لكل رطل) من وزن الجسم خلال مدة 3 أيام.</li></ul><p>&nbsp;</p><p><strong>لعلاج الذأبة الحمامية:</strong></p><ul><li>للبالغين: متوسط الجرعة المبدئية 400 ملجم مرة واحدة أو مرتين في اليوم.</li></ul><p>&nbsp;</p><p><strong>لعلاج التهاب المفاصل الروماتويدي:</strong></p><ul><li>للبالغين: الجرعة المبدئية العادية 400 - 600&nbsp;ملجم في اليوم.</li></ul><p>&nbsp;</p><p><strong>بالنسبة إلى المرضى الذين يأخذون الدواء ارثوسيف للوقاية من الملاريا:</strong></p><ul><li>قد يطلب منك الطبيب البدء في استخدام هذا الدواء قبل أسبوعين من السفر إلى المنطقة التي يحُتمل أن تتعرض فيها للإصابة بالملاريا . سيساعدك هذا على التعرف على استجابة جسمك للدواء. كما ستساعد الطبيب أيضًا على تغيير هذا الدواء بدواء آخر إذا كنت تعاني من حساسية من هذا الدواء.</li><li>يجب أيضًا الاستمرار في استخدام هذا الدواء أثناء وجودك في المنطقة المنطقة المصابة بالملاريا ولمدة 8 أسابيع أخرى بعد مغادرة تلك المنطقة لأن طفيل الملاريا له دورة حياة معقدة وقد يظل موجودًا في جسمك لبعض الوقت. وليس هناك دواء يوفر الوقاية الكاملة من الملاريا. ورغم ذلك؛ لحمايتك قدر المستطاع؛ من المهم الاستمرار في استخدام هذا الدواء طوال المدة التي حددها لك الطبيب. كذلك، إذا أصُبت بالحمى أثناء سفرك أو خلال شهرين بعد مغادرتك للمنطقة الموبوءة، فيجب استشارة الطبيب على الفور.</li></ul><p>&nbsp;</p><p><strong>بالنسبة إلى المرضى الذين يستخدمون الدواء ارثوسيف لعلاج التهاب المفاصل أو الذئبة:</strong></p><ul><li>يجب استخدام هذا الدواء بصفة منتظمة حسب تعليمات الطبيب للحصول على المفعول المنشود منه. قد تمر عدة أشهر قبل شعورك بالفائدة الكاملة لهذا الدواء.</li></ul><p>&nbsp;</p><p><u><strong>أ- في حالة تناول جرعة زائدة من أقراص ارثوسيف:</strong></u><br />مركبات ٤-أمينوكينولين تمتص بسرعة جدا وتستوعب تماما بعد الابتلاع، أو زيادة الجرعة بشكل عرضي، أو نادرا مع جرعات أقل في المرضى الذين يعانون الحساسية، قد تحدث الأعراض السمية في غضون ۳۰ دقيقة. تتألف هذه المجموعة من الصداع، والنعاس، واضطرابات بصرية، وانهيار القلب والأوعية الدموية، والتشنجات، تليها توقف الجهاز التنفسي المفاجئ والمبكر والسكتة القلبية.</p><p>&nbsp;</p><p>علاج الأعراض ويجب أن يكون فوريا مع الإخلاء الفوري من المعدة عن طريق التقيؤ (في المنزل، قبل وسائل النقل إلى المستشفى) أو غسل المعدة حتى يتم إفراغ المعدة تماما.</p><p>الاتصال بممارس الرعاية الصحية، مستشفى قسم الطوارئ أو مركز مراقبة السموم الإقليمية فورا.</p><p>&nbsp;</p><p><u><strong>ب- الجرعة الفائتة:</strong></u><br />في حالة نسيان جرعة من الدواء، تناولها بمجرد أن تتذكر. ولكن إذا كان وقت الجرعة التالية قد حان تقريبًا، فلا تأخذ الجرعة الفائتة وخذ الجرعة التي حان قتها حسب الجدول المنتظم الذي تسير عليه. ولا تأخذ جرعات مزدوجة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>قد يسبب الدواء تأثيرات غير مرغوب فيه إلى جانب مفعوله الطبي المفيد. وعلى الرغم من أنه قد لا تحدث جميع الآثار الجانبية للدواء، فإنها تستدعي العناية الطبية حال حدوثها. عند استخدام هذا الدواء لفترات قصيرة؛ تكون الآثار الجانبية نادرة عادة. لكن، عند استخدامه لفترات طويلة و/أو بجرعات عالية؛ يزيد احتمال حدوث آثار جانبية وقد تكون خطيرة.</p><p>&nbsp;</p><p>يجب استشارة الطبيب فورا حال حدوث أي من الآثار الجانبية التالية:</p><p>&nbsp;</p><p><strong>آثار جانبية غير شائعة:</strong> عدم وضوح الرؤية أو أي اضطراب آخر في الإبصار - قد يحدث هذا الأثر الجانبي أيضًا أو يتفاقم بعد التوقف عن استخدام هذا الدواء;</p><p><strong>آثار جانبية نادرة: </strong>اختلاجات (نوبات صرع)، ضعف زائد في العضلات، تغيرات مزاجية أو عقلية، طنين أو أزيز في الأذنين أو أي شكل من أشكال فقدان السمع، احتقان الحلق والحمى، نزيف غير عادي أو كدمات، تعب غير عادي، ضعف أعراض الجرعة المفرطة: نعاس، صداع، استثارة زائدة.</p><p>قد تحدث آثار جانبية أخرى لا تحتاج عادة إلى عناية طبية. قد تزول هذه الآثار الجانبية أثناء العلاج مع تكيف الجسم مع الدواء .</p><p><br />ولكن، يجب استشارة الطبيب حال استمرار أي من تلك الآثار الجانبية لمدة طويلة أو تطوره بشكل مزعج:<br />&nbsp;</p><p><strong>آثار جانبية شائعة:&nbsp;</strong>إسهال، صعوبة في الرؤية عند القراءة، صداع، حكة )أكثر شيوعا في المرضى ذوي البشرة السوداء(، فقدان الشهية، غثيان أو قيء؛ تقلصات أو ألم في المعدة;</p><p><strong>غير شائعة:&nbsp;</strong>ابيضاض الشعر أو زيادة تساقط الشعر؛ تلون الجلد بلون أسود مزرق، وكذلك الأظافر أو داخل الفم، دوخة أو دوار، عصبية أو أرق ،طفح جلدي.</p><p>قد تحدث آثار جانبية أخرى غير المذكورة أعلاه في بعض المرضى. إذا لاحظت أي آثار جانبية أخرى؛ فاستشر الطبيب.</p><p>يجب استشارة الطبيب على الفور إذا حدث اضطراب في الرؤية أو صعوبة في القراءة أو أي مشكلات أخرى في الإبصار أثناء أو بعد العلاج لفترة طويلة. قد يطلب منك الطبيب إجراء فحص طبي على عينيك بواسطة طبيب عيون.</p><p>قد يسبب الدواء ارثوسيف رؤية غير طبيعية للألوان أو عدم وضوح الرؤية أو صعوبة في القراءة أو غير ذلك من اضطرابات الإبصار. وقد يسبب أيضًا الدوار أو الدوخة لدى بعض الأشخاص. احرص على التعرف على كيفية استجابة جسمك لهذا الدواء قبل قيادة مركبات أو استخدام آلات أو فعل أي شيء آخر ينطوي على مخاطر حال تعرضك للدوخة أو ضعف الانتباه أو عدم القدرة على الإبصار بشكل جيد. ويجب استشارة الطبيب خصوصًا إذا كانت تلك الأعراض الجانبية مزعجة. مع العلم بأن الملاريا تنتشر بواسطة البعوض .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>احفظ جميع الأدوية بعيدًا عن متناول الأطفال. الجرعات المفرطة من ارثوسيف خطيرة جدًا على الأطفال.</li><li>يخزن في درجة حرارة أقل من 25 درجة مئوية.</li><li>لا يخُزن في دورة المياه ولا بالقرب من حوض المطبخ أو أماكن أخرى رطبة.</li><li>لا تحتفظ بالأدوية منتهية الصلاحية أو التي لا تحتاج إليها. احرص على إبعاد أي دواء غير مستعمل عن متناول الأطفال.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي هيدروكسي كلوروكوين سلفات.<br />المكونات الاخرى هي كروسكارميلوز الصوديوم، ستيرات المغنيسيوم، كوليدال ثاني أكسيد السيليكون، ميكروكريستالين السليلوز، هيدروكسي بروبيل السليلوز، هيدروكسي ميثيل سليلوز ۲۹۱۰ يو اس بي اي فايف، البولي ايثيلين جلايكول ۸۰۰۰ ، ثاني أكسيد التيتانيوم يو اس بي والماء منقى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>حبة بيضاء، على شكل كبسولة، ثنائي التحدب، قرص مغلف مع حواف مسطحة. جانب واحد منقوش تتوفر الاقراص في علبة تحوي ۱۰۰ قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة أبوتكس، في مدينة تورنتو، مقاطعة أونتاريو، M9L 1T9 كندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             تمت آخر مراجعة في: 03\2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ARTHOSAVE

Hydroxychloroquine Sulfate Tablets USP 200 mg

(Expressed as the  salt) Equivalent to 155 mg Hydroxychloroquine
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                In addition to hydroxychloroquine sulfate, each tablet contains the non-medicinal ingredients croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, microcrystalline cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyethylene glycol, and titanium dioxide.
Hydroxychloroquine sulfate is a white or practically white, crystalline powder. It is odorless and has a bitter taste. Its aqueous solution has a pH of about 4.5. It is freely soluble in water; practically insoluble in alcohol, chloroform and ether.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each white, capsule-shaped, biconvex film-coated tablet engraved ‘HCQ 200’ on one side contains hydroxychloroquine sulfate 200 mg. Available in bottles of 100 and 500 tablets, unit dose packages of 30 and 100 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Treatment and Prevention of Malaria</strong></p><p>ARTHOSAVE is also indicated for the suppressive treatment of malaria and the treatment of acute attacks of malaria due to Plasmodium vivax, P. malariae, P. ovale and susceptible strains of P. falciparum.</p><p>&nbsp;</p><p>ARTHOSAVE (hydroxychloroquine sulfate) is not effective against chloroquine-resistant strains of P. falciparum. In recent years it has been found that certain strains of P. falciparum located in certain parts of the world have become resistant to 4-aminoquinoline compounds (including hydroxychloroquine) as shown by the fact that normally adequate doses have failed to prevent or cure clinical malaria or parasitemia.</p><p>Treatment with quinine or other specific forms of therapy is therefore advised for patients infected with a resistant strain of parasites.</p><p>&nbsp;</p><p><strong>Treatment of Rheumatoid Arthritis</strong></p><p>ARTHOSAVE (hydroxychloroquine sulfate) is indicated for use in patients with the following disorders who have not responded satisfactorily to drugs with less potential for serious side effects: lupus erythematosus (chronic discoid or systemic) and acute or chronic rheumatoid arthritis.</p><p>&nbsp;</p><p>In the treatment of rheumatoid arthritis, if objective improvement (such as reduced joint swelling, increased mobility) does not occur within 6 months, the drug should be discontinued. Safe use of the drug in the treatment of juvenile arthritis has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Lupus Erythematosus:</u></strong></p><p>Initially, the average <em>adult </em>dose is 400 mg (= 310 mg base) once or twice daily. This may be continued for several weeks or months, depending on the response of the patient. For prolonged maintenance therapy, a smaller dose, from 200 mg to 400 mg (= 155 to 310 mg base) daily will frequently suffice.</p><p>&nbsp;</p><p>The incidence of retinopathy has been reported to be higher when this maintenance dose is exceeded.</p><p>&nbsp;</p><p><strong><u>Rheumatoid Arthritis</u><u>:</u></strong></p><p>The compound is cumulative in action and will require several weeks to exert its beneficial therapeutic effects, whereas minor side effects may occur relatively early. Several months of therapy may be required before maximum effects can be obtained. If objective improvement (such as reduced joint swelling, increased mobility) does not occur within six months, the drug should be discontinued. Safe use of the drug in the treatment of juvenile rheumatoid arthritis has not been established.</p><p>&nbsp;</p><p><em><u>Initial dosage</u>: In adults</em>, from 400 mg to 600 mg (= 310 mg to 465 mg base) daily, each dose to be taken with a meal or a glass of milk. In a small percentage of patients, troublesome side effects may require temporary reduction of the initial dosage. Later (usually from five to ten days), the dose may gradually be increased to the optimum response level, often without return to side effects.</p><p>&nbsp;</p><p><em><u>Maintenance dosage</u>: </em>When a good response is obtained (usually in four to twelve weeks), the dosage is reduced by 50 percent and continued at a usual maintenance level of 200 mg to 400 mg (= 155 to 310 mg base) daily, each dose to be taken with a meal or a glass of milk. The incidence of retinopathy has been to be higher when this maintenance dose is exceeded. Should a relapse occur after medication is withdrawn, therapy may be resumed or continued on an intermittent schedule if there are no ocular contraindications.</p><p>&nbsp;</p><p>Corticosteroids and salicylates may be used in conjunction with this compound, and they can generally be decreased gradually in dosage or eliminated after the drug has been used for several weeks. When gradual reduction of steroid dosage is indicated, it may be done by reducing every 4 to 5 days the dose of cortisone by no more than from 5 to 15 mg; of hydrocortisone from 5 to 10 mg; of prednisolone and prednisone from 1 to 2.5 mg; of methylprednisolone and triamcinolone from 1 to 2 mg; and of dexamethasone from 0.25 mg to 0.5 mg.</p><p>&nbsp;</p><p><strong><u>Malaria</u></strong></p><p><u>Suppression</u>: <em>In adults</em>, 400 mg (= 310 mg base) on exactly the same day of each week. <em>In infants and children</em>, the weekly suppressive dosage is 5 mg, calculated as base per kg of body weight, but should not exceed the adult dose regardless of weight.</p><p>&nbsp;</p><p>If circumstances permit, suppressive therapy should begin two weeks prior to exposure. However, failing this, in adults, an initial double (loading) dose of 800 mg (= 620 mg base) or in children 10 mg base/kg may be taken in two divided doses, six hours apart. The suppressive therapy should be continued for eight weeks after leaving the endemic area.</p><p>&nbsp;</p><p><u>Treatment of the acute attack</u>: <em>In adults</em>, an initial dose of 800 mg (= 620 mg base), followed by 400 mg (= 310 mg base) in 6 to 8 hours and 400 mg (= 310 mg base) on each of two consecutive days (total 2 g hydroxychloroquine sulfate or 1.55 g base). An alternative method, employing a single dose of 800 mg (=620 mg base) has also proved effective.</p><p>&nbsp;</p><p>The dosage in adults may also be calculated on the basis of body weight but this method is preferred for infants and children.</p><p>&nbsp;</p><p><em>For infants and children</em>, a total dose representing 32.3 mg hydroxychloroquine sulfate per kg (=25 mg base/kg) of body weight is administered in 3 days as follows:</p><p>&nbsp;</p><p><u>First dose</u>: 12.9 mg hydroxychloroquine sulfate per kg (10 mg base/kg), but not exceeding a single dose of 800 mg hydroxychloroquine sulfate (= 620 mg base).</p><p>&nbsp;</p><p><u>Second dose</u>: 6.5 mg hydroxychloroquine sulfate (= 5 mg base/kg), (but not exceeding a single dose of 400 mg hydroxychloroquine sulfate [= 310 mg base]) 6 hours after first dose.</p><p>&nbsp;</p><p><u>Third dose</u>: 6.5 mg hydroxychloroquine sulfate (= 5 mg base/kg) 18 hours after second dose.</p><p>&nbsp;</p><p><u>Fourth dose</u>: 6.5 mg hydroxychloroquine sulfate (= 5 mg base/kg) 24 hours after third dose.</p><p>&nbsp;</p><p>For radical cure of <em>vivax </em>and <em>malariae </em>malaria, concomitant therapy with an 8-aminoquinoline compound is necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The use of ARTHOSAVE (hydroxychloroquine sulfate) is contraindicated

•	In the presence of retinal or visual field changes attributable to any 4-aminoquinoline compound,

•	In patients with known hypersensitivity to 4-aminoquinoline compounds.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Use in Children</u></strong></p><p>The safety and efficacy of hydroxychloroquine have not been fully established in rheumatoid arthritis or systemic lupus erythematosus in children. Young children are particularly sensitive to the toxic effects of 4aminoquinones, therefore patients should be warned to keep hydroxychloroquine out of reach of children.</p><p>&nbsp;</p><p>Fatalities following the accidental ingestion of chloroquine, sometimes in small doses (0.75 or 1 g in one 3 year old child) have been reported.</p><p>&nbsp;</p><p><strong><u>Retinal Damage</u></strong></p><p>Irreversible retinal damage has been observed in some patients who had received long-term or high-dosage 4aminoquinoline therapy for discoid and systemic lupus erythematosus, or rheumatoid arthritis. Retinopathy has been reported to be dose related.</p><p>&nbsp;</p><p>When prolonged high dose therapy with any antimalarial compound is contemplated, initial (baseline) and periodic (every three months) ophthalmic examinations (including visual acuity, expert slit-lamp, fundoscopic, and visual field tests) should be performed.</p><p>&nbsp;</p><p>If there is any indication of abnormality in the visual acuity, visual field, or retinal macular areas (such as pigmentary changes, loss of foveal reflex), or any visual symptoms (such as light flashes and streaks) which are not fully explainable by difficulties of accommodation or corneal opacities, the drug should be discontinued immediately and the patient closely observed for possible progression. Retinal changes (and visual disturbances) may progress even after cessation of therapy.</p><p>&nbsp;</p><p><strong><u>Neuromuscular/Muscular Changes</u></strong></p><p>All patients on long-term high dose therapy with this preparation should be questioned and examined periodically (including the testing of knee and ankle reflexes) to detect any evidence of muscular weakness. If weakness occurs, discontinue the drug.</p><p>&nbsp;</p><p><u><strong>Use in Patients with Psoriasis/Porphyria</strong></u></p><p>Use of hydroxychloroquine in patients with psoriasis may precipitate a severe attack of psoriasis. When used in patients with porphyria, the condition may be exacerbated. Hydroxychloroquine should not be used in these conditions unless in the judgement of the physician the benefit to the patient outweighs the possible hazard.</p><p>&nbsp;</p><p><strong><u>Precautions</u></strong></p><p>Dermatological reactions to hydroxychloroquine may occur, and, therefore, proper care should be exercised when it is administered to any patient receiving a drug with a significant tendency to produce dermatitis.</p><p>&nbsp;</p><p>The methods recommended for early diagnosis of &ldquo;chloroquine retinopathy&rdquo; consist of (1) fundoscopic examination of the macula for fine pigmentary disturbances or loss of the foveal reflex and (2) examination of the central visual field with a small red test object for pericentral or paracentral scotoma or determination of retinal thresholds to red. Any unexplained visual symptoms, such as light flashes or streaks also should be regarded with suspicion as possible manifestations of retinopathy.</p><p>For treatment of serious toxic symptoms, see Symptoms and Treatment of Overdosage.</p><p>&nbsp;</p><p><strong><u>Laboratory Tests</u></strong></p><p>Periodic blood cell counts should be made if patients are given prolonged therapy. If any severe blood disorder appears which is not attributable to the disease under treatment, discontinuation of the drug should be considered. The drug should be administered with caution in patients having G-6-</p><p>PD (glucose-6-phosphate dehydrogenase) deficiency.</p><p>&nbsp;</p><p><strong><u>Cardiac Effects, including Cardiomyopathy and QT prolongation:</u></strong></p><p>Post marketing cases of life-threatening and fatal cardiomyopathy have been reported with use of hydroxychloroquine as well as with use of chloroquine. Patients may present with atrioventricular block, pulmonary hypertension, sick sinus syndrome or with cardiac complications. ECG findings may include atrioventricular, right or left bundle branch block. Signs or symptoms of cardiac compromise have appeared during acute and chronic treatment. Clinical monitoring for signs and symptoms of cardiomyopathy is advised, including use of appropriate diagnostic tools such as ECG to monitor patients for cardiomyopathy during hydroxychloroquine therapy. Chronic toxicity should be considered when conduction disorders (bundle branch block/atrio-ventricular heart block) or biventricular hypertrophy are diagnosed. If cardiotoxicity is suspected, prompt discontinuation of Hydroxychloroquine may prevent life-threatening complications.</p><p>&nbsp;</p><p>Hydroxychloroquine prolongs the QT interval. Ventricular arrhythmias and torsades de pointes have been reported in patients taking hydroxychloroquine Therefore, Hydroxychloroquine should not be administered with other drugs that have the potential to prolong the QT interval</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ARTHOSAVE (hydroxychloroquine sulfate) should be used with caution with known hepatotoxic drugs and in alcoholics or patients with hepatic or renal disease. Concomitant use of medicaments including phenylbutazone, gold, and other drugs known to cause sensitization and dermatitis should be avoided.</p><p>&nbsp;</p><p>Digoxin levels may be increased by hydroxychloroquine and should therefore be monitored. Hydroxychloroquine interferes with antibody response to human diploid rabies vaccine.</p><p>As hydroxychloroquine may enhance the effects of a hypoglycaemic treatment, a decrease in doses of insulin or antidiabetic drugs may be required.</p><p>&nbsp;</p><p><strong><u>Drugs that prolong QT interval and other arrhythmogenic drugs:</u></strong></p><p>hydroxychloroquine prolongs the QT interval and should not be administered with other drugs that have the potential to induce cardiac arrhythmias. Also, there may be an increased risk of inducing ventricular arrhythmias if &nbsp;hydroxychloroquine is used concomitantly with other arrhythmogenic drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Usage of this drug during pregnancy and breast-feeding should be avoided except in the suppression or treatment of malaria when in the judgment of the physician the benefit outweighs the possible hazard. It should be noted that radioactively-tagged chloroquine administered i.v. to pregnant, pigmented CBA mice passed rapidly across the placenta. It accumulated selectively in the melanin structures of the fetal eyes and was retained in the ocular tissues for 5 months after the drug had been eliminated from the rest of the body. It is also known to be excreted in breast milk and that infants are sensitive to 4-aminoquinolines.</p><p>&nbsp;</p><p>In patients taking hydroxychloroquine for systemic or discoid lupus erythematosus or rheumatoid arthritis who are planning a pregnancy and wish to minimize drug exposure to the fetus, the 40 day half-life and large volume of distribution of the drug requires about 6 months cessation of therapy before conception. Cessation of therapy is associated with a risk of exacerbation of disease. In patients already taking hydroxychloroquine for systemic lupus erythematosus at the time they become pregnant, discontinuation of the drug may increase the risk to the fetus because of reactivation of the disease. Although safety data are limited, at least for SLE, consideration may be given to continuing hydroxychloroquine. For RA, the arthritis may improve during therapy, allowing consideration for stopping the hydroxychloroquine, but there is a risk of post-partum flare.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hydroxychloroquine may cause blurred vision, difficulty in reading, or other change in vision. It may also cause some people to become dizzy or lightheaded. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are dizzy or are not alert or able to see well. If these reactions are especially bothersome, check with your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Malaria</u></p><p>Following administration in doses adequate for malarial suppression or the treatment of an acute malarial attack, mild and transient headache, dizziness, and gastrointestinal complaints (diarrhea, anorexia, nausea, abdominal cramps and, on rare occasions, vomiting) may occur.</p><p>&nbsp;</p><p><u>Lupus Erythematosus and Rheumatoid Arthritis</u></p><p>Not all of the following reactions have been observed during long-term therapy with every 4- aminoquinoline compound, but they have been reported with at least one of them and should be borne in mind when drugs of this class are administered. Adverse effects with different compounds vary in type and frequency.</p><p>&nbsp;</p><p>CNS Reactions: Irritability, nervousness, emotional changes, nightmares, psychosis, headache, dizziness, vertigo, tinnitus, nystagmus, nerve deafness, convulsions, and ataxia.</p><p>&nbsp;</p><p>Neuromuscular Reactions: Skeletal muscle palsies or skeletal muscle myopathy or neuromyopathy leading to progressive weakness and atrophy of proximal muscle groups which may be associated with mild sensory changes, depression of tendon reflexes and abnormal nerve conduction.</p><p>&nbsp;</p><p><u>Ocular Reactions</u></p><p>A.&nbsp;&nbsp;&nbsp; Ciliary body:</p><p>Disturbance of accomodation with symptoms of blurred vision. This reaction is dose-related and reversible with cessation of therapy.</p><p>&nbsp;</p><p>B.&nbsp;&nbsp;&nbsp;&nbsp; Cornea:</p><p>Transient edema, punctate to lineal opacities, decreased corneal sensitivity. The corneal changes, with or without accompanying symptoms (blurred vision, halos around lights, photophobia), are fairly common, but reversible. Corneal deposits may appear as early as three weeks following initiation of therapy. The incidence of corneal changes and visual side effects appears to be considerably lower with hydroxychloroquine than with chloroquine.</p><p>&nbsp;</p><p>C.&nbsp;&nbsp;&nbsp;&nbsp; Retina: Macula:</p><p>Edema, atrophy, abnormal pigmentation (mild pigment stippling to a &ldquo;bull&rsquo;s- eye&rdquo; appearance), loss of foveal reflex, increased macular recovery time following exposure to a bright light (photo-stress test), elevated retinal threshold to red light in macular paramacular and peripheral retinal areas. Other fundus changes include optic disc pallor and atrophy, attenuation of retinal arterioles, fine granular pigmentary disturbances in the peripheral retina and prominent choroidal patterns in advanced stage.</p><p>&nbsp;</p><p>D.&nbsp;&nbsp;&nbsp; Visual field defects:&nbsp;</p><p>pericentral or paracentral scotoma, central scotoma with decreased visual acuity, rarely field constriction and Abnormal color vision.</p><p>&nbsp;</p><p>The most common visual symptoms attributed to the retinopathy are: reading and seeing difficulties (words, letters, or parts of objects missing), photophobia, blurred distance vision, missing or blacked out areas in the central or peripheral visual field, light flashes and streaks.</p><p>Retinopathy appears to be dose related and has occurred within several months (rarely) to several years of daily therapy; a small number of cases have been reported several years after antimalarial drug therapy was discontinued. It has not been noted during prolonged use of weekly doses of the 4-aminoquinoline compounds for suppression of malaria.</p><p>Patients with retinal changes may have visual symptoms or may be asymptomatic (with or without visual field changes). Rarely scotomatous vision or field defects may occur without obvious retinal change.</p><p>&nbsp;</p><p>Retinopathy may progress even after the drug is discontinued. In a number of patients, early retinopathy (macular pigmentation sometimes with central field defects) diminished or regressed completely after therapy was discontinued. Paracentral scotoma to red targets (sometimes called &ldquo;premaculopathy&rdquo;) is indicative of early retinal dysfunction which is usually reversible with cessation of therapy.</p><p>A small number of cases of retinal changes have been reported as occurring in patients who received only hydroxychloroquine. These usually consisted of alteration in retinal pigmentation which was detected on periodic ophthalmologic examination; visual field defects were also present in some instances. A case of delayed retinopathy has been reported with loss of vision starting 1 year after administration of hydroxychloroquine had been discontinued.</p><p>&nbsp;</p><p><u>Dermatologic Reactions:</u></p><p>Bleaching of the hair, alopecia, pruritus, skin and mucosal pigmentation, photosensitivity, and skin eruptions (urticarial, morbilliform, lichenoid, maculopapular, purpuric, erythema annulare centrifugum, StevensJohnson syndrome, acute generalized exanthematous pustulosis, and exfoliative dermatitis.</p><p>&nbsp;</p><p><u>Hematologic Reactions:</u></p><p>Various blood dyscrasias such as aplastic anemia, agranulocytosis, leukopenia, thrombocytopenia (hemolysis in individuals with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency).</p><p>&nbsp;</p><p><u>Gastrointestinal Reactions:</u></p><p>anorexia, nausea, vomiting, diarrhea, and abdominal cramps.</p><p>&nbsp;</p><p><u>Miscellaneous Reactions:</u></p><p>isolated cases of abnormal liver function and fulminant hepatic failure, weight loss, lassitude, exacerbation or precipitation of porphyria and non-sensitive psoriasis. Cardiomyopathy has been rarely reported with high daily dosages of hydroxychloroquine.</p><p>&nbsp;</p><p><u>Cardiac disorders:</u></p><p>Cardiomyopathy which may result in cardiac failure and in some cases a fatal outcome Hydroxychloroquine prolongs the QT interval. Ventricular arrhythmias and torsade de pointes have been reported in patients taking Hydroxychloroquine</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Saudi Arabia:</em></strong></p><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><ul><li>Fax: +966‐11‐205‐7662</li><li>Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.</li><li>Toll free phone: 8002490000</li><li>E‐mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Other</em></strong><strong><em> </em></strong><strong><em>GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The 4-aminoquinoline compounds are very rapidly and completely absorbed after ingestion, and in accidental overdosage, or rarely with lower dosages in hypersensitive patients, toxic symptoms may occur within 30 minutes. These consist of headache, drowsiness, visual disturbances, cardiovascular collapse, and convulsions, followed by sudden and early respiratory and cardiac arrest.</p><p>&nbsp;</p><p>The electrocardiogram may reveal atrial standstill, nodal rhythm, prolonged intraventricular conduction time, and progressive bradycardia leading to ventricular fibrillation and/or arrest.</p><p>&nbsp;</p><p>Treatment is symptomatic and must be prompt with immediate evacuation of the stomach by emesis (at home, before transportation to the hospital) or gastric lavage until the stomach is completely emptied. If finely powdered, activated charcoal is introduced by the stomach tube, after lavage, and within 30 minutes after ingestion of the tablets, it may inhibit further intestinal absorption of the drug. To be effective, the dose of activated charcoal should be at least five times the estimated dose of hydroxychloroquine ingested.</p><p>Convulsions, if present, should be controlled before attempting gastric lavage. If due to cerebral stimulation, cautious administration of an ultrashort acting barbiturate may be tried but, if due to anoxia, it should be corrected by oxygen administration, artificial respiration or, in shock with hypotension, by vasopressor therapy. Because of the importance of supporting respiration, tracheal intubation or tracheostomy, followed by gastric lavage, may also be necessary. Exchange transfusions have been used to reduce the level of 4- aminoquinoline drug in the blood.</p><p>&nbsp;</p><p>A patient who survives the acute phase and is asymptomatic should be closely observed for at least 6 hours. Fluids may be forced, and sufficient ammonium chloride (8 g daily in divided doses for adults) may be administered for a few days to acidify the urine to help promote urinary excretion in cases of both overdosage and sensitivity.</p><p>&nbsp;</p><p>If serious toxic symptoms occur from overdosage or sensitivity, it has been suggested that ammonium &nbsp;chloride (8 g daily in divided doses for adults) be administered orally 3 or 4 days a week for several months after therapy has been stopped, as acidification of the urine increases renal excretion of 4-aminoquinoline compounds by 20 to 90%. However, caution must be exercised in patients with impaired renal function and/or metabolic acidosis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Rheumatoid Arthritis &amp; Lupus Erythematosus</u></p><p>Overall efficacy of hydroxychloroquine as a lower toxicity anti-rheumatic alternative has been reported on various occasions.</p><p>&nbsp;</p><p>Of 108 rheumatoid arthritis patients treated with hydroxychloroquine (200-400 mg/day) for at least 6 months a 63% response rate has been reported. A similar study reports a 70% response rate with 12% of patients showing complete remission. In trials comparing 300 patients randomized to hydroxychloroquine and 292 to placebo. A statistically significant benefit was observed with hydroxychloroquine. Overall efficacy appeared to be moderate, but the low toxicity profile of hydroxychloroquine should be considered in the treatment of rheumatoid arthritis.</p><p>&nbsp;</p><p>Hydroxychloroquine (400 mg/day) was also found to be equally effective as intramuscular gold (50 mg / week titrated to response) in the treatment of rheumatoid arthritis. However, hydroxychloroquine demonstrated a beneficial effect on the lipid profiles of patients with rheumatoid arthritis, by significantly increasing high density lipoprotein (HDL) levels by a median 15%.</p><p>&nbsp;</p><p>In a double-blind randomized study, acitretin and hydroxychloroquine were found to be equally effective for the treatment of lupus erythematosus in 58 patients. Acitetrin 50 mg/day (n= 28) and hydroxychloroquine 500 mg/day (n=30) was compared with improvement obtained in 46% and 50% of subjects for acitetrin and hydroxychloroquine respectively.</p><p>However, the incidence of side effects was significantly higher in the patients administered acitetrin (4 subjects) requiring discontinuation of therapy compared to hydroxychloroquine (0 subjects).</p><p>&nbsp;</p><p>Human volunteers demonstrated tolerance to administration of eight tablets (one tablet = 155 to 160 mg) in a single dose, with no more side effects than mild gastrointestinal disturbances lasting for two to ten hours (mean peak plasma level = 635 mcg/L).</p><p>&nbsp;</p><p>The primary concern with hydroxychloroquine use is the possibility of retinal toxicity. This maculopathy however is a rare event, with an incidence of &lt;1%. There is no evidence that the retinal toxicity of hydroxychloroquine is related to the maximum blood concentration of the drug. The potential risk of maculopathy has been reported to be related to cumulative dose (&gt;800 g), duration of the treatment (&gt;10 years), and age (&gt;65 years). A daily dosage of greater than 6.0- 6.5 mg/kg, especially in patients with abnormal hepatic or renal function, is also associated with an increased risk.</p><p>&nbsp;</p><p>Of 1,207 patients surveyed using hydroxychloroquine, only 6 patients (0.12%) revealed toxicity. Patients receiving &lt;6.5 mg/kg of the drug daily did not exhibit any definite retinal toxicity due to hydroxychloroquine.</p><p>&nbsp;</p><p>Of ninety-nine patients treated with 400 mg/day hydroxychloroquine sulfate for at least one year (median period of 33 months), only three patients revealed mild retinotoxic effects but no patient sustained permanent visual acuity. A seven year follow-up of these patients revealed no increased incidence or severity of toxic effects.</p><p>&nbsp;</p><p>Both chloroquine and hydroxychloroquine have a high affinity for melanin; thus highest accumulations of the drug in the body are observed in the epidermis and retina, which may account for their retinal toxicity.</p><p>However, hydroxychloroquine is preferred to chloroquine because of a lower risk of retinal toxicity. It has been proven that the incidence of retinopathy during hydroxychloroquine treatment is much lower that with chloroquine in equipotent doses. Occurrences of retinal toxicity with hydroxychloroquine have been found to be almost exclusively at higher than recommended doses.16,17,18 &nbsp;The incidence of retinopathy during hydroxychloroquine treatment apears to be lower than with chloroquine given in equipotent doses, however, lower efficacies have also been reported. In man, the lethal dose of chloroquine has been estimated at 3-5 g in adults and 0.75-1 g in young children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As a weak base, hydroxychloroquine absorption is complete but rapidly absorbed from the small intestine (GI tract). Extent of absorption may vary depending on inter-subject variability but is not affected by fed or fasted states during dosing.</p><p>&nbsp;</p><p>There is no report on the saturability of the absorption processes of hydroxychloroquine. Hydroxychloroquine is about 40-45% protein bound (albumin and &alpha;1-glycoprotein) and has a bioavailability of approximately 74% (range 70-80%). Following a single oral dose of hydroxychloroquine sulfate 200 mg (1 tablet) to healthy subjects, mean blood peak concentration (Cmax) of 244 ng/mL (range: 188-427 ng/mL) was achieved within 2-4.5 hours (Tmax) after dosing. Plasma drug concentrations were found to be about 7 to 8 times lower and more variable than blood concentrations.</p><p>The drug is extensively distributed into body tissues with a large apparent volume of distribution (Vd) (5,500- 2,200 L and 44,000 - 21,000 L calculated from blood and plasma data respectively). Higher concentrations of the drug were observed in the brain, kidneys, liver, spleen, lung and erythrocytes than in plasma. Both chloroquine and hydroxychloroquine have a high affinity for melanin; thus highest concentrations were observed in the epidermis, retina, choroid and ciliary body of the eye. Small amounts of hydroxychloroquine (about 3.2 mcg of the drug over 48 hours) were detected in breast milk from a woman given a dose of 800 mg.</p><p>&nbsp;</p><p>Hydroxychloroquine is partially metabolised in liver. First pass metabolism of the drug is not significant (6%). Metabolism of the drug proceeds by the formation of a series of degradation products which are in the order of 1) the secondary amine, desethylhydroxychloroquine or desethylchloroquine; 2) the primary amine, bisdesethyl-chloroquine; 3) the 4&rsquo;-aldehyde derivative, a minor portion reduced further to alcohol; and 4) the 4&rsquo;-carboxy derivative. The major metabolite is desethylhydroxychloroquine, which may also have antiplasmodial activity. Hydroxychloroquine conjugated with glucuronide has been found to be excreted in the bile.</p><p>&nbsp;</p><p>The terminal half-life (t1/2) of hydroxychloroquine was estimated from blood data at 50-16 days (about 32 days in plasma) following an oral administration of hydroxychloroquine sulfate 200 mg to healthy volunteers.</p><p>&nbsp;</p><p>Elimination of hydroxychloroquine from the body appears to be gradual and takes place in a biphasic manner. The proportion of the absorbed dose undergoing hepatic metabolism is estimated to be about 30 - 60%. Slow renal clearance of the drug has been reported accounting for 15 to 25% of total clearance and can be detected for several months after discontinuation of the treatment. Following a single dose of hydroxychloroquine sulfate 200 mg, the cumulative urinary excretions of the unchanged drug and its metabolites over a 86 day period were about 16% and 1.3% of the administered dose respectively.</p><p>&nbsp;</p><p>Unabsorbed drug (up to 15-24%) is excreted in the feces. Unknown amounts are deposited into dermal cells and sloughed off by the skin. Elimination of the remaining unaccounted amount of the administered dose has been suggested as via hepatic metabolism followed by biliary excretion, and shedding pigmented tissue such as skin. However, some reports indicate that between 21 and 47% of the drug ingested is excreted unchanged.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Acute Toxicity</u></strong></p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1027" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:402.75pt;margin-top:-85.1pt;width:6.9pt;height:7.35pt;
 z-index:-26512;mso-position-horizontal-relative:page'>
 <v:imagedata src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Species</strong></p></td><td style="vertical-align:top"><p><strong>Route Of Administration</strong></p></td><td style="vertical-align:top"><p><strong>Acute </strong><strong>LD50 mg/base/kg</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Mouse</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Intravenous Intraperitoneal Oral</p></td><td style="vertical-align:top"><p>45-2</p><p>182</p><p>1,880-133</p></td></tr><tr><td style="vertical-align:top"><p>Dog</p></td><td style="vertical-align:top"><p>Intramuscular</p></td><td style="vertical-align:top"><p>&gt;25</p></td></tr><tr><td style="vertical-align:top"><p>Rabbit</p></td><td style="vertical-align:top"><p>Intravenous</p></td><td style="vertical-align:top"><p>12.4</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><u>Signs of Toxicity</u>:</strong></p><p>Rapid onset of hypoventilation, cardiovascular collapse with bradycardia, peripheral vasodilation, arrhythmias and convulsions.</p><p>&nbsp;</p><p><strong><u>Subacute and Chronic Toxicity</u></strong></p><p>In rats, a five day oral dose test reported a tolerated daily dose greater than 250 mg/kg and less than 400 mg/kg.</p><p>Hydroxychloroquine was administered 6 days a week for 13 weeks in dogs. It was found that dogs readily tolerated oral doses of 20 mg/ kg of hydroxychloroquine. A similar study using chloroquine killed three out of four animals within 19 days. A ten month study in monkeys demonstrated a tolerated daily oral dose of more than 60 mg/base/kg.</p><p>Hydroxychloroquine appeared to generally be less toxic than chloroquine in animal toxicity studies, however, this was associated with lower tissue levels of drug.</p><p>&nbsp;</p><p><strong><u>Special Toxicity Studies Reproduction / Teratogenicity</u></strong></p><p>Hydroxychloroquine crosses the placental barrier in mice and shows affinity for melanin containing tissues such as retina, iris and choroid of the eye.</p><p>&nbsp;</p><p><strong><u>Carcinogenicity / Mutagenicity</u></strong></p><p>Reports of related carcinogenic or mutagenic actions or hydroxychloroquine have not been well documented.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table style="width:237px" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:234px"><p><strong>Name</strong><strong> </strong><strong>of the excipients(s)</strong></p></td></tr><tr><td style="vertical-align:top; width:234px"><p>Croscarmellose Sodium</p></td></tr><tr><td style="vertical-align:top; width:234px"><p>Magnesium Stearate</p></td></tr><tr><td style="vertical-align:top; width:234px"><p>Colloidal Silicon Dioxide</p></td></tr><tr><td style="vertical-align:top; width:234px"><p>Microcrystalline Cellulose (PH 102)</p></td></tr><tr><td style="vertical-align:top; width:234px"><p>Hydroxypropyl Cellulose, Type LF</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Hydroxypropyl Methylcellulose 2910 E5</p></td></tr><tr><td style="vertical-align:top"><p>Polyethylene Glycol 8000</p></td></tr><tr><td style="vertical-align:top"><p>Titanium Dioxide</p></td></tr><tr><td style="vertical-align:top"><p>Purified Water</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Primary packaging:</strong> Bottle pack.</p><p>Bottle: White, opaque, HDPE round bottle (75cc), 38 mm</p><p>Cap: 38 mm-400, blue polypropylene cap with Lift &ldquo;n&rdquo; Peel tab</p><p><strong>Secondary packaging:</strong> Carton</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03/2019.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>